Cardiotoxicity and myocardial hypoperfusion associated with anti‐vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer

Dobbin, Stephen J.H.; Mangion, Kenneth; Berry, Colin; Roditi, Giles; Basak, Susmita; Sourbron, Steven; White, Jeff; Venugopal, Balaji; Touyz, Rhian M.; Jones, Robert J.; Petrie, Mark C.; Lang, Ninian N.

doi:10.1002/ejhf.1847

Cited by 14 publications

(18 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…385 HF can develop as a consequence of the toxic effects of anti-cancer therapy (cardiotoxicity). 383,[386][387][388] In patients treated with immune checkpoint inhibitors (ICIs), pharmacovigilance data analysis reported an incidence of 4.2% of cardiac events, including myocarditis, which was often burdened by a high mortality. 389,390 The incidence of cardiac events was higher in those patients with dual ICI therapy.…”

Section: Cancer Treatmentmentioning

confidence: 99%

Heart failure: an update from the last years and a look at the near future

et al. 2022

View full text Add to dashboard Cite

In the last years, major progress occurred in heart failure (HF) management. Quadruple therapy is now mandatory for all the patients with HF with reduced ejection fraction. Whilst verciguat is becoming available across several countries, omecamtiv mecarbil is waiting to be released for clinical use. Concurrent use of potassium-lowering agents may counteract hyperkalaemia and facilitate renin-angiotensin-aldosterone system inhibitor implementations. The results of the EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction (EMPEROR-Preserved) trial were confirmed by the Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction (DELIVER) trial, and we now have, for the first time, evidence for treatment of also patients with HF with preserved ejection fraction. In a pre-specified meta-analysis of major randomized controlled trials, sodium-glucose co-transporter-2 inhibitors reduced all-cause mortality, cardiovascular (CV) mortality, and HF hospitalization in the patients with HF regardless of left ventricular ejection fraction. Other steps forward have occurred in the treatment of decompensated HF. Acetazolamide in Acute Decompensated Heart Failure with Volume Overload (ADVOR) trial showed that the addition of intravenous acetazolamide to loop diuretics leads to greater decongestion vs. placebo. The addition of hydrochlorothiazide to loop diuretics was evaluated in the CLOROTIC trial. Torasemide did not change outcomes, compared with furosemide, in TRANSFORM-HF. Ferric derisomaltose had an effect on the primary outcome of CV mortality or HF rehospitalizations in IRONMAN (rate ratio 0.82; 95% confidence interval 0.66-1.02; P = 0.070). Further options for the treatment of HF, including device therapies, cardiac contractility modulation, and percutaneous treatment of valvulopathies, are summarized in this article.

show abstract

Section: Cancer Treatmentmentioning

confidence: 99%

Heart failure: an update from the last years and a look at the near future

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Cancer is a risk factor for HF 20–23 . In a prospective cohort study of 146 817 post‐menopausal women, Leedy et al 24 .…”

Section: Comorbiditiesmentioning

confidence: 99%

“…Cancer is a risk factor for HF. [20][21][22][23] In a prospective cohort study of 146 817 post-menopausal women, Leedy et al 24 showed that HF was associated with an increased risk of subsequent cancer [hazard ratio (HR) 1.28, 95% confidence interval (CI) 1.11-1.48], namely obesity-related, lung and colorectal cancers. In patients treated with immune checkpoint inhibitors (ICIs), pharmacovigilance data analysis reported an incidence of 4.2% of cardiac events, including myocarditis, which was often burdened by a high mortality.…”

Section: Cardio-oncologymentioning

confidence: 99%

October 2021 at a glance: focus on imaging, biomarkers and comorbidities

Tomasoni

Adamo

Metra

2021

European J of Heart Fail

View full text Add to dashboard Cite

“…The resulting myocardial hypoxia leads to sustained expression of hypoxia-inducible factor alpha (HIF-), which was demonstrated to be sufficient to cause cardiomyopathy 36 , 37 . Indeed, enhanced vascular permeability and reversible microvascular vasoconstriction have been reported in patients receiving therapies targeting VEGF and PDGF receptor (VEGFR and PDGFR, respectively) 38 . Moreover, this mechanism of toxicity well explains the clinical observation that cardiomyopathy associated with anti-VEGFR/PDGFR agents is reversible 39 .…”

Section: Role Of Non-cardiomyocytes In Cancer Treatment-related Cardiotoxicitymentioning

confidence: 99%

Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart

Tocchetti

Ameri

Boer

et al. 2020

Cardiovascular Research

View full text Add to dashboard Cite

In the Western countries cardiovascular disease and cancer are the leading causes of death in the ageing population. Recent epidemiological data suggest that cancer is more frequent in patients with prevalent or incident cardiovascular disease, in particular heart failure. Indeed, there is a tight link in terms of shared risk factors and mechanisms between heart failure and cancer. Heart failure induced by anticancer therapies has been extensively studied, primarily focusing on the toxic effects that antitumor treatments exert on cardiomyocytes. In this Cardio-Oncology update, members of the ESC WGs of Myocardial Function and of Cellular Biology of the Heart discuss novel evidence interconnecting cardiac dysfunction and cancer via pathways in which cardiomyocytes may be involved, but are not central. In particular, the multiple roles of cardiac stromal cells (endothelial cells, fibroblasts) and inflammatory cells are highlighted. Also, the gut microbiota is depicted as a new player at the crossroads between heart failure and cancer. Finally, the role of non-coding RNAs in Cardio-Oncology is also addressed. All these insights are expected to fuel additional research efforts in the field of Cardio-Oncology.

show abstract

Cardiotoxicity and myocardial hypoperfusion associated with anti‐vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer

Cited by 14 publications

References 6 publications

Heart failure: an update from the last years and a look at the near future

Heart failure: an update from the last years and a look at the near future

October 2021 at a glance: focus on imaging, biomarkers and comorbidities

Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart

Contact Info

Product

Resources

About